View in EDS HTML Full Text PDF Full Text

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.

Saved in:
Bibliographic Details
Title: Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
Authors: Blauvelt A; Blauvelt Consulting, LLC, Annapolis, MD, USA., Kircik L; Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Indiana University School of Medicine, Indianapolis, IN, USA., Schlesinger T; Clinical Research Center of the Carolinas, Charleston, SC, USA.; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Pierce E; Eli Lilly and Company, Indianapolis, IN, USA., Burge R; Eli Lilly and Company, Indianapolis, IN, USA.; University of Cincinnati, Cincinnati, OH, USA., Behling M; Syneos Health, Morrisville, NC, USA., Atwater AR; Eli Lilly and Company, Indianapolis, IN, USA., ElMaraghy H; Eli Lilly and Company, Indianapolis, IN, USA., Armstrong A; Keck School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Source: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2442720. Date of Electronic Publication: 2025 Jan 06.
Publication Type: Journal Article
Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1471-1753
DOI:10.1080/09546634.2024.2442720